Logo image of TCRT

ALAUNOS THERAPEUTICS INC (TCRT) Stock Fundamental Analysis

NASDAQ:TCRT - Nasdaq - US98973P3091 - Common Stock - Currency: USD

2.47  -0.01 (-0.4%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TCRT. TCRT was compared to 568 industry peers in the Biotechnology industry. While TCRT has a great health rating, there are worries on its profitability. TCRT has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TCRT had negative earnings in the past year.
TCRT had a negative operating cash flow in the past year.
In the past 5 years TCRT always reported negative net income.
In the past 5 years TCRT always reported negative operating cash flow.
TCRT Yearly Net Income VS EBIT VS OCF VS FCFTCRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

The Return On Assets of TCRT (-169.87%) is worse than 86.44% of its industry peers.
TCRT has a Return On Equity of -226.85%. This is in the lower half of the industry: TCRT underperforms 71.30% of its industry peers.
Industry RankSector Rank
ROA -169.87%
ROE -226.85%
ROIC N/A
ROA(3y)-217.74%
ROA(5y)-158.17%
ROE(3y)-293.94%
ROE(5y)-216.39%
ROIC(3y)N/A
ROIC(5y)N/A
TCRT Yearly ROA, ROE, ROICTCRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TCRT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCRT Yearly Profit, Operating, Gross MarginsTCRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200K -400K -600K

More info and screens

7

2. Health

2.1 Basic Checks

TCRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TCRT has been reduced compared to 1 year ago.
The number of shares outstanding for TCRT has been reduced compared to 5 years ago.
There is no outstanding debt for TCRT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TCRT Yearly Shares OutstandingTCRT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
TCRT Yearly Total Debt VS Total AssetsTCRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

TCRT has an Altman-Z score of -469.08. This is a bad value and indicates that TCRT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TCRT (-469.08) is worse than 98.24% of its industry peers.
TCRT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -469.08
ROIC/WACCN/A
WACC10.2%
TCRT Yearly LT Debt VS Equity VS FCFTCRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 3.98 indicates that TCRT has no problem at all paying its short term obligations.
The Current ratio of TCRT (3.98) is comparable to the rest of the industry.
TCRT has a Quick Ratio of 3.98. This indicates that TCRT is financially healthy and has no problem in meeting its short term obligations.
TCRT has a Quick ratio (3.98) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.98
Quick Ratio 3.98
TCRT Yearly Current Assets VS Current LiabilitesTCRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

2

3. Growth

3.1 Past

TCRT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.90%, which is quite good.
TCRT shows a strong growth in Revenue. In the last year, the Revenue has grown by 80.00%.
Measured over the past years, TCRT shows a very negative growth in Revenue. The Revenue has been decreasing by -70.71% on average per year.
EPS 1Y (TTM)9.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.43%
Revenue 1Y (TTM)80%
Revenue growth 3Y-70.71%
Revenue growth 5YN/A
Sales Q2Q%300%

3.2 Future

The Earnings Per Share is expected to grow by 13.09% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y243.33%
EPS Next 2Y32.92%
EPS Next 3Y21.64%
EPS Next 5Y13.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TCRT Yearly Revenue VS EstimatesTCRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
TCRT Yearly EPS VS EstimatesTCRT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150 -200

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

TCRT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 2.82, which indicates a rather cheap valuation of TCRT.
Based on the Price/Forward Earnings ratio, TCRT is valued cheaply inside the industry as 99.12% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of TCRT to the average of the S&P500 Index (21.32), we can say TCRT is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 2.82
TCRT Price Earnings VS Forward Price EarningsTCRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TCRT Per share dataTCRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

TCRT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TCRT's earnings are expected to grow with 21.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.92%
EPS Next 3Y21.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TCRT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALAUNOS THERAPEUTICS INC

NASDAQ:TCRT (4/21/2025, 11:11:19 AM)

2.47

-0.01 (-0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31 2025-03-31/amc
Earnings (Next)05-13 2025-05-13
Inst Owners4.51%
Inst Owner Change-0.01%
Ins Owners13.78%
Ins Owner Change2.66%
Market Cap4.05M
Analysts43.33
Price TargetN/A
Short Float %4.28%
Short Ratio3.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2.82
P/S 450.09
P/FCF N/A
P/OCF N/A
P/B 1.96
P/tB 1.96
EV/EBITDA N/A
EPS(TTM)-1.98
EYN/A
EPS(NY)0.88
Fwd EY35.51%
FCF(TTM)-3.03
FCFYN/A
OCF(TTM)-3.03
OCFYN/A
SpS0.01
BVpS1.26
TBVpS1.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -169.87%
ROE -226.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-217.74%
ROA(5y)-158.17%
ROE(3y)-293.94%
ROE(5y)-216.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.98
Quick Ratio 3.98
Altman-Z -469.08
F-Score4
WACC10.2%
ROIC/WACCN/A
Cap/Depr(3y)5.45%
Cap/Depr(5y)202.23%
Cap/Sales(3y)1315.8%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.43%
EPS Next Y243.33%
EPS Next 2Y32.92%
EPS Next 3Y21.64%
EPS Next 5Y13.09%
Revenue 1Y (TTM)80%
Revenue growth 3Y-70.71%
Revenue growth 5YN/A
Sales Q2Q%300%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y83.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y83.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y83.51%
OCF growth 3YN/A
OCF growth 5YN/A